25-September-2018: According to Grand View Research, Inc., the worldwide specialty generics market is predicted to achieve USD 174.9 billion by 2025. Specialty Generics are the generic forms of specialty pharmaceutical products. They are less expensive as compared to other branded specialty drugs. They can be used in several conditions such as oncology, inflammatory conditions, multiple sclerosis, hepatitis C, and others.
On 30 December 2017, Natco Pharma introduced a generic version of tenofovir alafenamide (TAF) 25mg. The medicine can be used to treat hepatitis B. The company has launched this TAF generic drug under the brand Tafnat in India.
On 30 December 2017, Natco Pharma introduced a generic version of tenofovir alafenamide (TAF) 25mg. The medicine can be used to treat hepatitis B. The company has launched this TAF generic drug under the brand Tafnat in India.
On 13, December 2017, Pfizer announced that the US FDA approved product Ixifi (PF-06438179, infliximab-qbtx). The product can be used to treat Crohn's disease, rheumatoid arthritis, pediatric Crohn’s disease, ankylosing spondylitis, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.
On 17 June 2017, Lupin Limited launched its bupropion hydrochloride extended release pills USP (XL), 150 mg and 300 mg, which has been approved by the US FDA. The product is the AB rated generic correspondent to Wellbutrin XL tablets, developed by Valeant Pharmaceuticals North America, LLC. The product is designed for preventing seasonal affective disorder (SAD) in adults and major depressive disorder (MDD).
On 15 May 2017, Dr Reddy’s Laboratories introduced the generic form of velpatasvir 100mg and sofosbuvir 400mg fixed-dose combination. This product is available with brand name name Resof Total in India and can be used for treating chronic hepatitis C.
On 1 March 2017, Teva Pharmaceutical Industries Ltd., introduced a generic Pristiq1 (desvenlafaxine) extended-release tablets, 25, 50 and 100 mg, in the U.S. These medicines are a norepinephrine reuptake inhibitor (SNRI) and serotonin, which can be used for treating MDD.
Factors such as increasing occurrence of chronic diseases like cancer, hepatitis C, multiple sclerosis, and others have augmented the demand for cost-effective medicines can drive the specialty generics market during the forecast period (2014 to 2025). In addition, patent expiration of many specialty medicines can boost the market demand.
Key players operating in the market include Endo Pharmaceuticals, Inc.; Teva Pharmaceuticals USA, Inc.; Pfizer, Inc.; Valeant Pharmaceuticals International, Inc.; and Akorn, Inc.
In-Depth Research Report On Specialty Generics Market:
https://www.grandviewresearch.com/industry-analysis/specialty-generics-market
No comments:
Post a Comment